• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

iScience . Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model

tetano

Editor, Senior Moderator
iScience


. 2021 Feb 19;24(2):102054.
doi: 10.1016/j.isci.2021.102054. Epub 2021 Jan 9.
Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model


Sreelekshmy Mohandas[SUP] 1 [/SUP], Pragya D Yadav[SUP] 1 [/SUP], Anita Shete-Aich[SUP] 1 [/SUP], Priya Abraham[SUP] 1 [/SUP], Krishna Mohan Vadrevu[SUP] 2 [/SUP], Gajanan Sapkal[SUP] 1 [/SUP], Chandrashekhar Mote[SUP] 3 [/SUP], Dimpal Nyayanit[SUP] 1 [/SUP], Nivedita Gupta[SUP] 4 [/SUP], Vellimedu Kannappa Srinivas[SUP] 2 [/SUP], Manoj Kadam[SUP] 1 [/SUP], Abhimanyu Kumar[SUP] 1 [/SUP], Triparna Majumdar[SUP] 1 [/SUP], Rajlaxmi Jain[SUP] 1 [/SUP], Gururaj Deshpande[SUP] 1 [/SUP], Savita Patil[SUP] 1 [/SUP], Prasad Sarkale[SUP] 1 [/SUP], Deepak Patil[SUP] 1 [/SUP], Raches Ella[SUP] 2 [/SUP], Sai D Prasad[SUP] 2 [/SUP], Sharda Sharma[SUP] 1 [/SUP], Krishna M Ella[SUP] 2 [/SUP], Samiran Panda[SUP] 4 [/SUP], Balram Bhargava[SUP] 4 [/SUP]



Affiliations
Free PMC article

Abstract

The availability of a safe and effective vaccine would be the eventual measure to deal with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) threat. Here, we have assessed the immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidates BBV152A, BBV152B, and BBV152C in Syrian hamsters. Three dose vaccination regimes with vaccine candidates induced significant titers of SARS-CoV-2-specific IgG and neutralizing antibodies. BBV152A and BBV152B vaccine candidates remarkably generated a quick and robust immune response. Post-SARS-CoV-2 infection, vaccinated hamsters did not show any histopathological changes in the lungs. The protection of the hamster was evident by the rapid clearance of the virus from lower respiratory tract, reduced virus load in upper respiratory tract, absence of lung pathology, and robust humoral immune response. These findings confirm the immunogenic potential of the vaccine candidates and further protection of hamsters challenged with SARS-CoV-2. Of the three candidates, BBV152A showed the better response.

Keywords: Biological Sciences; Immunity; Immunology; Viral Microbiology; Virology.
 
Back
Top Bottom